As of January 24, 2024, analysts have been providing varied evaluations of Biogen (NASDAQ: BIIB) over the past three months. The following table summarizes the recent ratings by analysts, comparing sentiments over the last 30 days with those of the preceding months:
Rating Total Ratings Last 30 Days 1M Ago 2M Ago 3M Ago
Bullish 1 0 0 1 0
Somewhat Bullish 7 0 0 3 4
Indifferent 2 1 0 0 1
Somewhat Bearish 0 0 0 0 0
Bearish 0 0 0 0 0
The average 12-month price target for Biogen stands at $309.64, with a high estimate of $379.00 and a low estimate of $242.00. Let’s take a look at the most recent analyst actions and their impact on ratings and price targets:
– Colin Bristow from UBS has announced a Neutral rating with a current price target of $276.00.
– Eric Schmidt from Cantor Fitzgerald has maintained an Overweight rating with a price target of $311.00.
– Jay Olson from Oppenheimer has raised the rating to Outperform, setting a price target of $295.00, up from $280.00.
– Paul Matteis from Stifel has lowered the rating to Buy, establishing a price target of $287.00, down from $315.00.
– Danielle Brill from Raymond James has announced an Outperform rating with a price target of $283.00.
– Matthew Harrison from Morgan Stanley has raised the rating to Overweight, setting a price target of $373.00, up from $361.00.
– Evan Seigerman from BMO Capital has lowered the rating to Outperform, with a price target of $295.00, down from $314.00.
– Brian Abrahams from RBC Capital has raised the rating to Outperform, establishing a price target of $363.00, up from $351.00.
– Laura Chico from Wedbush has lowered the rating to Neutral, setting a price target of $239.00, down from $266.00.
– Mohit Bansal from Wells Fargo has raised the rating to Overweight, with a price target of $365.00, up from $343.00.
Based on 21 buy ratings, 6 hold ratings, and 0 sell ratings, the consensus rating for Biogen is a Strong Buy. Analysts predict a 24.04% upside for the stock based on 12-month forecasts. The company’s estimated EPS is $3.17, and it has 144,898,120 shares outstanding.
This information provides a comprehensive overview of recent analyst ratings and price targets for Biogen, reflecting the evolving sentiments and evaluations of financial experts.
BIIB Stock Performance on January 24, 2024: Analyzing Price Momentum and Potential Setback
BIIB Stock Performance on January 24, 2024: A Look at the Price Momentum
On January 24, 2024, Biogen Inc. (BIIB) experienced mixed performances, with the stock trading near the bottom of its 52-week range and below its 200-day simple moving average. As per data sourced from CNN Money, the stock’s price momentum was closely scrutinized by traders and investors.
One important factor to consider was the price change that occurred since the market last closed. BIIB shares had increased by $3.38, representing a rise of 1.36%. This increase was a positive sign for the stock, indicating a potential upward trend.
However, the pre-market trading session brought a slight setback for BIIB stock. The stock dropped $2.68, erasing some of the gains made in the previous session.
Trading near the bottom of its 52-week range suggests that BIIB shares were closer to their lowest price level in the past year. This could indicate that the stock was undervalued or facing some challenges that affected its performance.
Moreover, trading below its 200-day simple moving average could be seen as a bearish signal. The 200-day moving average is a widely followed technical indicator that provides an average price over the past 200 trading days. When a stock trades below this average, it suggests a potential downward trend.
Investors and traders closely monitor these price indicators to make informed decisions about buying or selling BIIB shares. The increase in price since the market last closed could be seen as a positive sign, but the subsequent drop in pre-market trading might have dampened some optimism.
It is important to note that stock market performance is influenced by various factors, including company-specific news, industry trends, economic indicators, and geopolitical events. Therefore, it is crucial to conduct thorough research and consider multiple factors before making any investment decisions.
In conclusion, on January 24, 2024, BIIB stock experienced a 1.36% rise in price since the market last closed. However, the stock dropped $2.68 in pre-market trading, indicating a potential setback. Trading near the bottom of its 52-week range and below its 200-day simple moving average suggests that BIIB shares were facing challenges or were undervalued. Traders and investors should carefully analyze these price indicators and consider other relevant factors before making any investment decisions.
Biogen Inc. Stock Performance: Mixed Results in Total Revenue, Net Income, and EPS
On January 24, 2024, Biogen Inc. (BIIB) experienced mixed results in its stock performance, as reflected in its financial data. The data reveals both positive and negative trends in the company’s total revenue, net income, and earnings per share (EPS).
Starting with the total revenue, Biogen reported a total revenue of $9.43 billion for the past year, which is a decrease of 9.32% compared to the previous year. However, the company’s total revenue for the third quarter of the same year stood at $2.44 billion, indicating a 3.58% increase since the previous quarter.
Moving on to the net income, Biogen’s net income for the past year was $3.05 billion. This figure represents a significant increase of 95.8% when compared to the previous year. However, the net income for the third quarter of the same year was -$68.10 million, indicating a substantial decrease of 111.51% since the previous quarter.
Lastly, the earnings per share (EPS) of Biogen showed a similar pattern. The EPS for the past year was $20.87, reflecting a notable increase of 100.63% compared to the previous year. However, the EPS for the third quarter of the same year stood at -$0.47, indicating a significant decrease of 111.57% since the previous quarter.
Overall, Biogen’s stock performance on January 24, 2024, showcased a mixture of positive and negative trends. While the company experienced a decrease in total revenue and net income since the previous year, it did witness an increase in total revenue and net income since the previous quarter. However, the significant decline in net income and EPS during the third quarter raises concerns about the company’s financial performance and profitability.
Investors and analysts will closely monitor Biogen’s future financial reports to determine whether the positive quarterly growth can be sustained and if the company can overcome the challenges faced during the third quarter. These financial indicators provide valuable insights into the company’s performance and can help investors make informed decisions about their investment in BIIB stock.
